Saturday 17 October 2026
Export TKNO’s income statement to Excel — free account
Alpha Teknova, Inc.
TKNO Healthcare Drug Manufacturers Specialty & Generic
Alpha Teknova, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $40.5 million, up 7.35% from fiscal 2024. In the quarter to June 2026, revenue grew 18.5%, EPS grew 14.3%, free cash flow grew 74.2% and total debt rose 1.43%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
7.08
0.52
−6.84%
Follow TKNO
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
8.32 | 5.02 | 3.71 | 6.97 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(167.31) | (439.90) | (46.12) | (646.81) | |
P/B ratio |
4.56 | 2.96 | 2.39 | 4.87 | |
Price to Tangible BV |
5.48 | 3.58 | 2.91 | 5.95 | |
EV/Sales |
8.20 | 4.91 | 3.69 | 6.97 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(35.78) | (23.02) | (19.53) | (48.54) | |
EV/FCF |
(31.11) | (20.33) | (17.03) | (41.41) | |
Quick Ratio |
3.93 | 3.44 | 3.40 | 3.32 | |
Current Ratio |
5.27 | 4.58 | 4.59 | 4.49 | |
Net Debt/EBITDA |
3.48 | 2.69 | 1.65 | 3.31 | |
Debt/Assets |
12.15% | 12.67% | 13.35% | 13.79% | |
Debt/Equity |
0.18 | 0.19 | 0.20 | 0.21 | |
Asset Turnover |
0.34 | 0.36 | 0.39 | 0.42 | |
Operating CF/Net income |
0.46 | 0.10 | 0.74 | 0.15 | |
Capex/Depreciation |
(0.27) | (0.22) | (0.15) | (0.08) | |
Interest Coverage |
(21.14) | (21.84) | (19.63) | (11.47) | |
Research and Development Expense of Revenue |
5.18% | 5.23% | 5.50% | 4.55% | |
Selling, General and Administrative Expense of Revenue |
61.16% | 70.55% | 64.87% | 56.91% | |
Intangible Assets out of Total Assets |
0.11 | 0.12 | 0.12 | 0.12 | |
Share Based Compensation of Revenue |
8.13% | 7.78% | 6.27% | 5.10% | |
Graham Net Nets |
0.00 | 0.00 | (0.01) | (0.01) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(5.65%) | (8.68%) | (11.07%) | (5.46%) | |
Free Cash Flow Yield |
(3.17%) | (4.82%) | (5.85%) | (2.41%) | |
Revenue per Share |
0.20 | 0.19 | 0.21 | 0.23 | |
Operating CF per Share |
(0.04) | (0.01) | (0.06) | (0.01) | |
Capex per Share |
(0.01) | (0.01) | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.04) | (0.02) | (0.07) | (0.01) | |
Cash per Share |
0.41 | 0.40 | 0.33 | 0.33 | |
Shareholders Equity per Share |
1.36 | 1.29 | 1.21 | 1.17 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.36 | 1.29 | 1.21 | 1.17 | |
Free Cash Flow |
(2.37) | (0.81) | (3.58) | (0.60) | |
Working Capital |
29.63 | 26.97 | 24.78 | 23.95 | |
Capital Expenditures |
(0.39) | (0.35) | (0.22) | (0.12) | |
Net Current Asset Value |
1.59 | (0.30) | (2.06) | (2.45) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.04 | 0.03 | 0.02 | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
4.87 | 4.47 | 5.64 | 5.27 | |
Average Payables |
1.03 | 1.10 | 1.59 | 1.32 | |
Average Inventory |
7.29 | 6.93 | 6.72 | 7.26 | |
Average Assets |
115.86 | 111.18 | 106.33 | 103.18 | |
Average Common Equity |
79.96 | 75.58 | 71.76 | 69.33 |
Columns are period end dates